{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:51Z","timestamp":1792093791101,"version":"4.4.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sosei Heptares"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Somatostatin receptor ligands have come to play a pivotal role in the treatment of both ACTH- and GH-secreting pituitary adenomas. Clinical efficacy averages 30-50%, thus a considerable number of patients with Cushing's disease or acromegaly remain unresponsive to this therapeutic approach. HTL0030310 is a new somatostatin receptor ligand selective for subtype 5 over subtype 2, thus with a different receptor profile compared to clinical somatostatin receptor ligands.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Assessment of the effect of HTL0030310 on hormone secretion in human ACTH- and GH-secreting pituitary adenomas in vitro.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Primary cultures from 3 ACTH-secreting and 5 GH-secreting pituitary adenomas were treated with 1, 10 and 100 nM HTL0030310 alone or with 10 nM CRH or GHRH, respectively. Parallel incubations with 10 nM pasireotide were also carried out. ACTH and GH secretion were assessed after 4 and 24 hour incubation; SSTR2, SSTR3, SSTR5, GH and POMC expression were evaluated after 24 hours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>HTL0030310 reduced unchallenged ACTH and POMC levels up to 50% in 2 ACTH-secreting adenomas and blunted CRH-stimulated ACTH\/POMC by 20-70% in all 3 specimens. A reduction in spontaneous GH secretion was observed in 4 GH-secreting adenomas and in 2 specimens during GHRH co-incubation. SSTRs expression was detected in all specimens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This first study on a novel somatostatin receptor 5-preferring ligand indicates that HTL0030310 can inhibit hormonal secretion in human ACTH- and GH-secreting pituitary adenomas. These findings suggest a potential new avenue for somatostatin ligands in the treatment of Cushing's disease and acromegaly.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvad171","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T03:43:29Z","timestamp":1703130209000},"page":"K8-K16","source":"Crossref","is-referenced-by-count":8,"title":["A novel somatostatin receptor ligand for human ACTH \u2013 and GH \u2013secreting pituitary adenomas"],"prefix":"10.1093","volume":"190","author":[{"given":"Daniela","family":"Regazzo","sequence":"first","affiliation":[{"name":"Endocrinology Unit, University Hospital of Padova , Padua 35143"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Avallone","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, University Hospital of Padova , Padua 35143"},{"name":"Department of Clinical and Molecular Science, Universit\u00e0 Politecnica delle Marche , Ancona 60126"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona P","family":"MacSweeney","sequence":"additional","affiliation":[{"name":"Sosei Heptares , Cambridge, CB21 6DG , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Sergeev","sequence":"additional","affiliation":[{"name":"Sosei Heptares , Cambridge, CB21 6DG , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Howe","sequence":"additional","affiliation":[{"name":"Sosei Heptares , Cambridge, CB21 6DG , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Godwood","sequence":"additional","affiliation":[{"name":"Sosei Heptares , Cambridge, CB21 6DG , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirstie A","family":"Bennett","sequence":"additional","affiliation":[{"name":"Sosei Heptares , Cambridge, CB21 6DG , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair J H","family":"Brown","sequence":"additional","affiliation":[{"name":"Sosei Heptares , Cambridge, CB21 6DG , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Barnes","sequence":"additional","affiliation":[{"name":"Sosei Heptares , Cambridge, CB21 6DG , United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4065-4677","authenticated-orcid":false,"given":"Gianluca","family":"Occhi","sequence":"additional","affiliation":[{"name":"Department of Biology, University of Padova , Padua 35143"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-5727","authenticated-orcid":false,"given":"Mattia","family":"Barbot","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, University Hospital of Padova , Padua 35143"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Faggian","sequence":"additional","affiliation":[{"name":"Laboratory Medicine, Department of Medicine, University Hospital of Padova , Padua 35143"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Tropeano","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Humanitas Clinical and Research Center IRCCS , Rozzano 20089"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-8247","authenticated-orcid":false,"given":"Marco","family":"Losa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Ospedale San Raffaele , Milan 20132"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lasio","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Humanitas Clinical and Research Center IRCCS , Rozzano 20089"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9396-3815","authenticated-orcid":false,"given":"Carla","family":"Scaroni","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, University Hospital of Padova , Padua 35143"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6065-7803","authenticated-orcid":false,"given":"Francesca","family":"Pecori Giraldi","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences & Community Health, University of Milan , Milan 20122 , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"issue":"5","key":"2024011021085730500_lvad171-B1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4240\/wjgs.v14.i5.383","article-title":"Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms","volume":"14","author":"Dai","year":"2022","journal-title":"World J Gastrointest Surg"},{"issue":"11","key":"2024011021085730500_lvad171-B2","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s40618-020-01335-0","article-title":"Somatostatin receptor expression and patients\u2019 response to targeted medical treatment in pituitary tumors: evidences and controversies","volume":"43","author":"Gatto","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2024011021085730500_lvad171-B3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"key":"2024011021085730500_lvad171-B4","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3389\/fendo.2020.00648","article-title":"Medical treatment of Cushing\u2019s disease: an overview of the current and recent clinical trials","volume":"11","author":"Pivonello","year":"2020","journal-title":"Front Endocrinol"},{"issue":"2","key":"2024011021085730500_lvad171-B5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2024011021085730500_lvad171-B6","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3389\/fendo.2019.00436","article-title":"Safety and efficacy of subcutaneous pasireotide in patients with Cushing\u2019s disease: results from an open-label, multicenter, single-arm, multinational, expanded-access study","volume":"10","author":"Fleseriu","year":"2019","journal-title":"Front Endocrinol"},{"issue":"4","key":"2024011021085730500_lvad171-B7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"Somatostatin receptors: structure, function, ligands, and new nomenclature","volume":"70","author":"G\u00fcnther","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"1-2","key":"2024011021085730500_lvad171-B8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000500812","article-title":"A new generation of somatostatin-dopamine analogue exerts potent antitumoral actions on pituitary neuroendocrine tumor cells","volume":"110","author":"Vazquez-Borrego","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"17","key":"2024011021085730500_lvad171-B9","doi-asserted-by":"crossref","first-page":"127391","DOI":"10.1016\/j.bmcl.2020.127391","article-title":"Discovery of nonpeptide 3,4-dihydroquinazoline-4-carboxamides as potent and selective sst2 agonists","volume":"30","author":"Zhao","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"2024011021085730500_lvad171-B10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1210\/jc.2008-2101","article-title":"Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas","volume":"94","author":"De Bruin","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2024011021085730500_lvad171-B11","first-page":"100","article-title":"Recent developments in the diagnosis and therapy of well-differentiated neuroendocrine tumours","volume":"76","author":"Hofland","year":"2018","journal-title":"Neth J Med"},{"issue":"2","key":"2024011021085730500_lvad171-B12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2024011021085730500_lvad171-B13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2024011021085730500_lvad171-B14","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1111\/jcmm.16173","article-title":"Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly","volume":"25","author":"Soukup","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"1","key":"2024011021085730500_lvad171-B15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s42000-021-00327-w","article-title":"Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy?","volume":"21","author":"Rass","year":"2022","journal-title":"Hormones"},{"issue":"2","key":"2024011021085730500_lvad171-B16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-16-0332","article-title":"Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro","volume":"231","author":"Ibanez-Costa","year":"2016","journal-title":"J Endocrinol"},{"issue":"4","key":"2024011021085730500_lvad171-B17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5","volume":"152","author":"Hofland","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2024011021085730500_lvad171-B18","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","article-title":"The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas","volume":"91","author":"Batista","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024011021085730500_lvad171-B19","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1365-2265.2008.03486.x","article-title":"Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing\u2019s disease","volume":"71","author":"Cukier","year":"2009","journal-title":"Clin Endocrinol"},{"issue":"9","key":"2024011021085730500_lvad171-B20","doi-asserted-by":"crossref","first-page":"e126128","DOI":"10.1111\/jne.12628","article-title":"Gene expression profiling in human corticotroph tumours reveals distinct, neuroendocrine profiles","volume":"30","author":"Cassarino","year":"2018","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"2024011021085730500_lvad171-B21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/EJE-15-0689","article-title":"The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing\u2019s disease","volume":"174","author":"Hayashi","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"2024011021085730500_lvad171-B22","author":"Congreve"},{"issue":"Suppl. 1","key":"2024011021085730500_lvad171-B23","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors","volume":"80","author":"Schmid","year":"2004","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2024011021085730500_lvad171-B24","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s12020-016-0990-x","article-title":"Proopiomelanocortin, glucocorticoid, and CRH receptor expression in human ACTH-secreting pituitary adenomas","volume":"55","author":"Cassarino","year":"2017","journal-title":"Endocrine"},{"issue":"3","key":"2024011021085730500_lvad171-B25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1677\/joe.0.1770373","article-title":"Corticotrophin-releasing activity of desmopressin in Cushing\u2019s disease. Lack of correlation between in vivo and in vitro responsiveness","volume":"177","author":"Pecori Giraldi","year":"2003","journal-title":"J Endocrinol"},{"issue":"12","key":"2024011021085730500_lvad171-B26","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1365-2826.2011.02213.x","article-title":"Responses to CRH and dexamethasone in a large series of human ACTH-secreting pituitary adenomas in vitro reveal manifold corticotroph tumoural phenotypes","volume":"23","author":"Pecori Giraldi","year":"2011","journal-title":"J Neuroendocrinol"},{"issue":"5","key":"2024011021085730500_lvad171-B27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/EJE-16-0831","article-title":"The GIP\/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp(-) somatotropinomas","volume":"176","author":"Regazzo","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2024011021085730500_lvad171-B28","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/clinchem\/hvaa125","article-title":"The digital MIQE guidelines update: minimum information for publication of quantitative digital PCR experiments for 2020","volume":"66","author":"Huggett","year":"2020","journal-title":"Clin Chem"},{"issue":"5","key":"2024011021085730500_lvad171-B29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/ERC-21-0258","article-title":"The GIP\/GIPR axis in medullary thyroid cancer: clinical and molecular findings","volume":"29","author":"Regazzo","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2024011021085730500_lvad171-B30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell"},{"issue":"6","key":"2024011021085730500_lvad171-B31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000059430","article-title":"Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells","volume":"75","author":"Strowski","year":"2002","journal-title":"Neuroendocrinology"},{"issue":"10","key":"2024011021085730500_lvad171-B32","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1210\/me.2007-0081","article-title":"Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation","volume":"21","author":"Ben-Shlomo","year":"2007","journal-title":"Mol Endocrinol"},{"issue":"2","key":"2024011021085730500_lvad171-B33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/eje.0.1300125","article-title":"Octreotide exerts different effects in vivo and in vitro in Cushing's disease","volume":"130","author":"Stalla","year":"1994","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2024011021085730500_lvad171-B34","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","article-title":"Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells","volume":"289","author":"van der Hoek","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"12","key":"2024011021085730500_lvad171-B35","doi-asserted-by":"crossref","first-page":"E1880","DOI":"10.1210\/jc.2013-1987","article-title":"Preoperative normalization of cortisol levels in Cushing\u2019s disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists","volume":"98","author":"van der Pas","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024011021085730500_lvad171-B36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11102-018-0926-y","article-title":"Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells","volume":"22","author":"Gatto","year":"2019","journal-title":"Pituitary"},{"issue":"3","key":"2024011021085730500_lvad171-B37","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF03349555","article-title":"Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion","volume":"13","author":"Ambrosi","year":"1990","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2024011021085730500_lvad171-B38","first-page":"1090","article-title":"Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide","volume":"78","author":"Renner","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024011021085730500_lvad171-B39","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1210\/jcem-71-6-1421","article-title":"Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase","volume":"71","author":"Spada","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024011021085730500_lvad171-B40","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024011021085730500_lvad171-B41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11102-020-01113-4","article-title":"Characterization of the ability of a second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells","volume":"24","author":"Cuny","year":"2021","journal-title":"Pituitary"},{"issue":"9","key":"2024011021085730500_lvad171-B42","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1172\/JCI119779","article-title":"Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors","volume":"100","author":"Shimon","year":"1997","journal-title":"J Clin Invest"},{"issue":"3","key":"2024011021085730500_lvad171-B43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2265.1992.tb02317.x","article-title":"Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels","volume":"37","author":"Hofland","year":"1992","journal-title":"Clin Endocrinol"},{"issue":"4","key":"2024011021085730500_lvad171-B44","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","author":"Hofland","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024011021085730500_lvad171-B45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.47162\/RJME.61.2.05","article-title":"Somatostatin receptors in normal and acromegalic somatotroph cells: the U-turn of the clinician to immunohistochemistry report\u2014a review","volume":"61","author":"Ionovici","year":"2020","journal-title":"Rom J Morphol Embryol"},{"issue":"4","key":"2024011021085730500_lvad171-B46","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024011021085730500_lvad171-B47","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1677\/jme.1.01876","article-title":"Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro","volume":"35","author":"Zatelli","year":"2005","journal-title":"J Mol Endocrinol"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvad171\/54705146\/lvad171.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/1\/K8\/55371565\/lvad171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/1\/K8\/55371565\/lvad171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T21:09:38Z","timestamp":1704920978000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/190\/1\/K8\/7484588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvad171","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,12,20]]}}}